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CLINICAL LABORATORY ASSESSMENT OF HEPATITIS C AND HIV COINFECTED PATIENTS
ACCORDING TO THE ANTIRETROVIRAL THERAPY RECEIVED
Roberto M. CARRASCO NAVARRO, Maria Cássia Jacintho MENDES-CORREA, Norma de Paula CAVALHEIRO & Antonio Alci BARONE
SUMMARY
During the year of 2001, a retrospective, descriptive study in order to determine the influence of the antiretroviral therapy
received by 111 HIV-HCV coinfected patients who had undergone at least one liver biopsy was conduced, 74 of them were treated
with a protease inhibitor regimen (WPI), and 37 with a non-protease inhibitor regimen (NPI). The main characteristics found
were: a young patient population (mean age 41 years old in both groups), composed in most part of male individuals (74.3% WPI
and 51.4% NPI) with previous risk factors for both infections (WPI 93.2% and NPI 89.2%). The most significant findings included
AIDS-defining disease (WPI 18.9% and NPI 13.5% of the cases), elevated hepatic enzyme levels (WPI: SGOT 52.1 and NPI 53.2),
absence of liver disease-related symptoms (16.2% for both groups), average CD4 count > 350 for both groups (WPI 362.2 and NPI
378.1), predominantly low-grade fibrosis in both populations (0-2 in 63.6% of WPI patients and in 80% of NPI patients), with
necro-inflammatory activity ranging from 5-7 in 51.3% and 42.9% of WPI patients and NPI patients, respectively. It is suggested
a sequential biopsy to better evaluate the evolution of the hepatic disease, according to the HAART regimen received.
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INTRODUCTION
Considering the common exposure points, there is an important
association between the mechanism of transmission of hepatitis C virus
(HCV) and human immunodeficiency virus (HIV), mainly in some
risk groups, such as intravenous drug users and previously, hemophiliac
patients9,27,29.
As of 1996, when the highly active antiretroviral therapy (HAART)
was first used in AIDS patients, potentially fatal co-morbidities, among
them HCV infection, have been considered increasingly important2,15,19.
HCV is a widespread disease worldwide. According to WHO data,
170 million people are infected with this virus in the whole world, 2-
4% of total population, and they are at risk for progression to
hepatocellular carcinoma22.
There is no local data concerning HCV infection in Brazil. A
research conducted among blood donors in the State of São Paulo found
anti-HCV positive serology in 0.84% of the subjects14; in São Paulo
City a prevalence of 1.42% (0.70-2.12%) was estimated using a
predictive statistical inference method based on a randomized sampling
stratified by gender, age, region of residence7.
In HIV positive populations, figures are highly inconsistent,
depending on the population studied; based on data from different
publications around the world, we can conclude that, depending on the
risk factors presented by the population studied, its prevalence may
vary. In populations consisting of 100% haemophilic patients, mainly
those studied before the availability of serologic tests to identify HCV,
the prevalence of coinfection among HIV infected patients is expected
to rise to 98% of this population26,28.
Figures should be less consistent when the population studied is
not homogeneous. An example of that are the data from non-
homogeneous populations originated from different American and
European studies, where the prevalence ranges from 7% in populations
with majority of males, current or previous intravenous drug users,
and a minor percentage of men who have sex with men and previous
history of blood transfusion, as found in studies performed in California,
U.S.A. and Toronto, Canada10,20, to 57% in populations consisting
primarily of male individuals, current or previous intravenous drug
users, and a minority of men who have sex with men as in a large
Spanish study16.
Previous studies conducted in Brazilian population at the same
site where the study of this publication was conducted showed a 17.7%
prevalence of coinfection14.
It is currently accepted that both infections are reciprocally
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influenced. This coinfluence was determined even before the
introduction of the highly active antiretroviral therapy (HAART) and
continues to be a controversial issue, including the decision of treat
the virus first24.
This project was designed as part of a protocol of the Laboratory
of Clinical Investigation on Hepatitis (LIM-47) intended to study the
evolution of HCV disease in HIV-coinfected patient, according to the
antiretroviral therapy given.
PATIENTS AND METHODS
The records of patients followed-up at the Extension Unit for
Treatment of HIV/AIDS Patients (Casa da AIDS) University of São
Paulo School of Medicine, Clinical Division of Infectious and Parasitic
Diseases of Hospital das Clínicas - University of São Paulo School of
Medicine (HC-FMUSP) during the year of 2001, were assessed. All
procedures were accepted by the Institutional Review Board of Hospital
das Clínicas.
We reviewed 3,512 active records so as to establish a coinfection
data basis, based on the antibody seropositivity status determined by
ELISA-HIV testing, Western Blot and ELISA-HCV. All patients were
positive to ELISA-HIV testing and Western Blot, 435 of them had not
been evaluated as to the presence of HCV by ELISA. The remaining
3,077 were tested as to the presence of HVC, being found at least one
positive serology in 468 patients. These patients were divided into
those who have undergone liver biopsy and those who have not. This
liver biopsy was performed at the physician’s discretion in all patients
with diagnosis of HCV infection, and the material was analysed at the
pathology laboratory of the HC-FMUSP. The grade of hepatic fibrosis
and necroinflammatory activity was determined according to the
Brazilian National Consensus on Chronic Hepatitis classification8. This
procedure was performed in 121 patients, who were divided into two
groups for analysis: Group 1 (with protease inhibitor regimen = WPI)
and group 2 (with non-protease inhibitor regimen = NPI). Ten patients
were excluded because they were HBV seropositive, were not using
antiretroviral drugs or had been treated with interferon for HCV
Infection.
Laboratory tests were performed at the HC-FMUSP Central
Laboratory; the Laboratory of Fundação Pró-Sangue-Hemocentro de
São Paulo, the Laboratory of Clinical Investigation on Hepatitis of
University of São Paulo School of Medicine (LIM-47) and at private
laboratories.
Once the records of patients coinfected with HIV-HCV virus and
followed-up at Casa da AIDS were identified, the following data were
collected: demographic data: gender, age, race, job; clinical data:
alcohol consumption, concomitant diseases, use of hepatotoxic drugs,
symptoms suggestive of hepatic disease (such as jaundice, liver
enlargement or esophageal varices), potential source of HIV-HCV
infection (such as blood transfusion, use of intravenous drug or
potentially infected material), adherence to the antiretroviral regimens
used; laboratory and viral data: liver biochemistry (SGOT, SGPT, GGT,
alkaline phosphatase, TB and F, PT), hematology, CD4 count, HIV
viral load, liver biopsy, qualitative PCR for hepatitis C virus.
Each patient was assigned to a different group according to the
antiretroviral therapy received for at least six months of study
(maximum time was not pre-defined), and the drugs were only
considered as a group (non-nucleoside, nucleoside and protease
inhibitors).
Data analysis: the qualitative variables were represented by both
absolute and relative frequency, and the quantitative ones by average,
standard-deviation (sd), median, minimum and maximum values.
RESULTS
Male patients were predominant in both groups, accounting for
74.3% of WPI group and 52.4% of NPI group, as well as Caucasian
patients with 80.6% and 94.4% of WPI and NPI groups, respectively.
Ethnic data were not available in the medical chart for 43 patients
from WPI group (58%) and 19 patients from NPI group (51%). In
average, the age at the time of first biopsy was exactly the same for
both groups (41 years old) and the standard-deviation was greater in
NPI group (8.3 years). Most patients in both groups had no professional
occupation and those who had it accounted for less than 10% in any of
the groups.
At least one risk factor, such as blood transfusion, use of illegal
intravenous drugs, use of potentially infected material, presence of
infected contact, risky sexual behavior or maternal-fetal transmission,
was identified in 93.2% of WPI patients and in 89.2% of NPI patients.
Risk factors were considered common for both infections.
Alcohol consumption was higher in WPI group (40% used to drink
alcohol regularly) than in the NPI group (42.3% did not use to drink
alcohol regularly).
During the follow-up period, most patients, either from WPI group
(81.1%) or NPI group (86.5%), presented no AIDS-defining infection
(according to the so-called Rio de Janeiro/Caracas criteria for AIDS
case that is officially recognized by the Brazilian regulations16. Most
patients from either group did not take hepatotoxic drugs during the
clinical follow-up period; WPI (91.9%) and NPI (86.5%).
Low incidence of liver disease-related symptoms was observed
for both groups (16.2%).
As showed in Table 2 mean CD4 count for both series was above
350, averaging 362.2 in WPI group and 378.1 in NPI group. There is
an apparent inconsistency between mean CD4 count and HIV viral
load that is normally inversely correlated: mean for WPI group: 53220.3
and mean for NPI group: 17946.7. In both treatment groups, viral load
was consistently high.
Based on the consensus of the Brazilian Society of Pathology, the
grade of fibrosis found in liver biopsies was mostly ≤ 2 in both groups;
63.6% and 80% for WPI group and NPI group, respectively.
The level of necro-inflammatory activity seen in liver biopsies,
ranged mostly between 5 and 7 for both groups, 51.3% for WPI group
and 42.9% for NPI group, respectively.
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DISCUSSION
Currently, there is no consensus on the influence of the different
antiretroviral regimens used in HIV treatment of patients coinfected
with HCV on the evolution of liver disease caused by HCV3,11.
The present paper is a preliminary study designed to determine
epidemiological, clinical and laboratorial characteristics of the patients
treated at Casa da AIDS in São Paulo, followed for at least six months,
receiving similar antiretroviral regimens and who had been submitted
to at least one liver biopsy at the time of evaluation. The group agrees
Table 3
Evaluation of the level of necro-inflammatory activity* in HIV-HCV
coinfected patients, according to the antiretroviral therapy received
Group
Inflammation WPI NPI
n % n  %
1 - 4 26  (33.3) 14  (40.0)
5 - 7 40 (51.3) 15 (42.9)
8 - 10 12 (15.4) 06 (17.1)
Total 78 (100.0) 35 (100.0)
*Measured as the sum of portal + periportal + parenchymatous changes seen, in
accordance with the Consensus of the Brazilian Society of Pathology8.
Table 2
Evaluation of fibrosis grade* in liver biopsy of HIV-HCV coinfected patients,
according to the antiretroviral therapy received
Group
Fibrosis WPI NPI
n % n  %
0 - 2 49 (63.6) 28 (80.0)
3 - 4 28 (36.4) 07 (20.0)
Total 77 (100.0) 35 (100.0)
* measured in accordance with the consensus of the Brazilian Society of
Pathology8.
Table 1
Biochemical and virological parameters assessed in HIV-HCV coinfected patients according to the antiretroviral therapy
Group
Parameters Normal Ranges WPI NPI
Minimum-Maximum Average (sd) Average (sd)
male/female(Units) Minimum-Maximum Minimum-Maximum
HIV Viral Load Minimal level of detection: 53220.3 (99443.3) 17946.7 (21930.9)
400 copies/ml 110.0 - 440000.0 100.00 - 58000.0
CD4 493-1.666 copies/UL 362.2 (187.5) 378.1 (175.3)
54.0 - 812.0 128.0 - 673.0
SGOT 10-44/36 (U/L) 52.1 (61.2) 53.2 (41.1)
9.0 - 433.0 10.0 - 136.0
SGPT 10-34/30 (U/L) 60.9 (56.4) 71.3 (56.2)
7.0 - 252.0 10.0 - 261.0
GGT 11(7)-50/32 (U/L) 89.4 (90.4) 122.9 (150.5)
8.0 - 385.0 9.0 - 559.0
Alkaline phosphatase 45/32-122/104 (U/L) 113.2 (54.3) 104.1 (34.8)
53.0 - 330.0 51.0 - 180.0
Total bilirubin 0.2-1.0 (mg/dl) 1.37 (0.8) 0.93 (0.5)
0.4 - 3.1 0.3 - 2.1
Direct bilirubin 0-0.4 (mg/dl) 0.4 (0.2) 0.3 (0.3)
0.1 – 1.2 0.1 – 1.4
Total protein 6.0-8.0 (g/dl) 7.9 (0.8) 8.0 (0.7)
6.0 - 9.4 7.0 - 9.2
Albumin 3.5-5.0 (g/dl) 4.2 (0.6) 4.3 (0.4)
3.0 - 5.2 3.3 - 4.7
Hemoglobin 13/12-18/16 (g/dl) 14.6 (1.4) 13.6 (1.6)
11.0 - 17.1 10.7 - 16.0
Platelet 140.0-450.0 (ml/mm3) 201015.9 (62081.2) 203071.4 (55970.2)
66000 - 341000 103000 - 309000
Prothrombin time >70% (%) 12.7 (1.7) 13.3 (1.4)
9.5 - 16.9 10.8 - 15.7
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with the concept that the best way to assess liver disease caused by
HCV is through sequential liver biopsies.
Populations of HIV/HCV coinfection studies are predominantly
young; the populations involved in studies conducted in Spain, France
and Italy were 40 years old or below4,6,13. The population included in
this study was in average 41 years old.
Regarding the educational level, studies have shown that in low
educational level population, the prevalence of HCV infection is higher
than in those subjects with a higher educational level7. Most patients
included in this study had low educational level, which correlates with
low social economical situation.
Identification of risk factors and their significance in coinfection
studies: Both virus can be transmitted through percutaneous exposure
to infected blood, sexual intercourse, and from the mother to her baby,
however the relative efficacy of these routes is variable23.
Nowadays, the concept of blood transfusion as a risk factor for
both viruses has almost disappeared due to the introduction of
serological tests in the 80´s, besides syringe exchange programs and
educational programs implemented in major cities, originally as an
immediate reaction to AIDS epidemy9,18,25.
Alcohol consumption has been associated with severe toxicity after
the use of HAART, as well as to a greater liver fibrosis progression
resulting from HCV coinfection3,17. It was also considered an
independent risk factor associated with the development of
hepatotoxicity after six months of treatment with HAART, being
observed a great difference in the occurrence of hepatotoxicity in
alcohol consumers either with or without coinfection1.
No difference was observed between both groups as to the use of
hepatotoxic drugs during their follow-up period at Casa da AIDS, being
only slightly greater in the group receiving protease inhibitors.
Toxicity at mitochondrial level has been described with the
concomitant use of Ribavirin in coinfected patients, and mainly
associated with the use of nucleoside reverse transcriptase inhibitors12.
Other drugs are known to interfere with the drugs used in HAART at
mitochondrial level, but the quantification of the coinfection injury,
has not been fully investigated.
The quantification of this injury is likely impossible, however, it
should be considered a potential conflicting variable in future studies.
Finally, our findings regarding low-grade fibrosis seen in most
patients from both groups, may be correlated with the lower mean age
of the patients, since the investigators who are currently studying
coinfection consider that an increase in progression of liver disease
caused by HCV infection occurs as of the age of 505,13,23 and that the
lower fibrosis grades found in younger population are due to the shorter
period of time elapsed since the beginning of the infection11,14,22.
Unfortunately, based on the data currently available in our clinic, it
was not possible to clearly determine how HAART therapy could
influence the progression of the liver disease in the population studied.
It is suggested that new biopsies are performed in order to determine
the difference in liver disease progression in both groups, according to
HAART therapy received.
RESUMO
Avaliação clínico-laboratorial de pacientes co-infectados com o
vírus da hepatite C e HIV-1 em relação ao tipo de terapia
antirretroviral recebida
Durante o ano de 2001, um estudo retrospectivo e descritivo foi
efetuado a fim de determinar a influência da terapia antirretroviral
recebida por 111 pacientes co-infectados HIV-HCV que tinham se
submetido ao menos a uma biopsia hepática. Destes, 74 foram tratados
com um regime contendo inibidor da protease (WPI) e 37 com um
regime do não contendo inibidor da protease (NPI). As características
principais encontradas eram: uma população de pacientes jovem (idade
média 41 anos em ambos os grupos), composta na maior parte por
indivíduos masculinos (74,3% WPI e 51,4% NPI) com fatores de risco
precedentes para ambas as infecções (WPI 93,2% e NPI 89,2%). Os
achados mais significativos incluíram doença definidora de AIDS (WPI
18,9% e NPI 13,5% dos casos), nível elevado de enzimas hepáticas
(WPI: SGOT 52.1 e NPI 53.2), ausência de sintomas relacionáveis à
doença hepática (16.2% para ambos os grupos), CD4 contagem média
350 para ambos os grupos (WPI 362.2 e NPI 378.1), fibrose
predominantemente de baixo grau em ambas as populações (0-2 em
63,6% de pacientes de WPI e em 80% de pacientes de NPI), com
atividade necro-inflamatória que varia de 5-7 em 51.3% e em 42,9%
de pacientes de WPI e de pacientes de NPI, respectivamente. Foi
concluído que uma nova biópsia hepática deveria ser executada em
todos os pacientes para determinar melhor qual a diferença no avanço
da doença em ambos os grupos.
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